Emerging Data and Future Directions for CDK4/6 Inhibitor Treatment of Patients With Hormone Receptor Positive HER2-non-amplified Metastatic Breast Cancer

Asia-Pacific Journal of Clinical Oncology - United Kingdom
doi 10.1111/ajco.13065
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

CDK4/6 Inhibitors for Hormone Receptor-Positive HER2-negative Metastatic Breast Cancer: Does One Size Fit All?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2019English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Current Approaches and Future Directions in the Treatment of HER2-positive Breast Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2013English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Breast Care
SurgeryOncology
2016English

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2009English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy